<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38689">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02143622</url>
  </required_header>
  <id_info>
    <org_study_id>CLJM716X2104</org_study_id>
    <nct_id>NCT02143622</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients</brief_title>
  <official_title>A Phase Ib/II, Multicenter Study of LJM716 in Combination With Cetuximab in Patients With Platinum-pretreated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices (BfArM)</authority>
    <authority>Canada: Health Canada</authority>
    <authority>France: National Agency for the Safety of Medicines and Health Products (MSNA)</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish whether LJM716 in combination with cetuximab is safe and has beneficial effects
      in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell
      carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase Ib: Target lesion change compared to baseline in patients, per RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of the preliminary anti-tumor activity of LJM716 in combination. Change in target lesion measurements, from baseline as per RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD)</measure>
    <time_frame>35 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose of LJM716 in combination with cetuximab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Percentage of Patients with an Objective Overall Response (OOR) per RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients with an Objective Overall Response (OOR) were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed by imaging, as pr RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the LJM716- cetuximab combination</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration versus time profiles blood PK parameters of LJM716 and cetuximab concentration</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>blood concentration versus time profiles blood PK parameters will be used to characterize the PK profiles of LJM716 and cetuximab concentration when used in combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR), per RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>BOR will be used to further assess the anti-tumor activity of LJM716-cetuximab combination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of response will be used to further assess the anti-tumor activity of LJM716-cetuximab combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) per RECIST 1.1</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival will be used to further assess the anti-tumor activity of LJM716-cetuximab combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) per RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival will be used to further assess the anti-tumor activity of LJM716-cetuximab combination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>LJM716+cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LJM716</intervention_name>
    <description>antibody</description>
    <arm_group_label>LJM716+cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>antibody</description>
    <arm_group_label>LJM716+cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Most recent regimen contains both platinum and cetuximab (Phase II, group B).

          -  ECOG Performance Status (PS) ≤ 2.

          -  Recovery from all AEs of previous anti-cancer therapies, to baseline or to CTCAE
             Grade ≤ 1, except for alopecia.

          -  Measurable disease as determined by RECIST v1.1.

        Exclusion Criteria:

          -  Previous anti-HER3 antibody treatment.

          -  Symptomatic brain metastasis.

          -  Prior systemic anti-cancer treatment, within a period of time that is shorter than
             the cycle length used for that treatment prior to starting study treatment.

          -  Prior anaphylactic or other severe infusion reaction to human immunoglobulin or
             antibody formulations.

          -  Inadequate end organ function.

          -  Ongoing diarrhea CTCAE Grade ≥ 2. Other protocol-defined inclusion/exclusion criteria
             may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona Dept of Oncology</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Ruggiero</last_name>
      <phone>480-342-3256</phone>
      <email>Ruggiero.vincent@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kelly K. Curtis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine Onc Dept</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jerri Tomassi</last_name>
      <phone>203-737-8367</phone>
      <email>Geraldine.tomassi@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Burtness</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Dept. of Onc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Raines</last_name>
      <phone>410-502-0678</phone>
      <email>craines1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center Onc Dept.</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0944</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne Miesterfeld</last_name>
      <phone>+1 734 232 0753</phone>
      <email>miestes@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Francis Paul Worden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center Fox Chase Cancer (2)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keith Salador</last_name>
      <phone>215-214-4297</phone>
      <email>keith.salador@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Ranee Mehra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center / UT Health Science Center Onc. Dept.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Creighton</last_name>
      <phone>210-450-1789</phone>
      <email>Regulatoryaffairs@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmad Wehbe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
